Abobotulinumtoxina is under clinical development by Ipsen and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Abobotulinumtoxina’s likelihood of approval (LoA) and phase transition for Musculoskeletal Pain took place on 05 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Abobotulinumtoxina Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Abobotulinumtoxina overview

Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure) is a neuromuscular blocking agent. It is formulated as lyophilized powder for solution, solution for intramuscular and subcutaneous route of administration. Dysport is indicated for the treatment of cervical dystonia in adults for reducing the severity of abnormal head position and neck pain in both toxin-naive and previously treated patients. It is also used for blepharospasm, spasmodic torticollis, hemifacial spasm, upper limb spasticity in adult patients, to decrease the severity of increased muscle tone in the elbow, wrist, and finger flexors, pediatric lower limb (PLL) spasticity in children two years of age and older, for the symptomatic treatment of focal spasticity affecting the lower limbs in adults.Dysport is also indicated for the symptomatic treatment of focal spasticity of upper limbs in pediatric cerebral palsy patients, two years of age and older. Dysport is indicated for the treatment of focal sapasticity affecting the upper and lower limbs in patients 2 years of age and older

The drug candidate is under development for the treatment of pediatric lower limb spasticity in EU, oromandibular dystonia, abdominal or thoracic chronic scar pain and pain associated with hallux valgus (Bunion). It is administered intramuscular and intradermal through. It was also under development for chronic low back pain, myofascial pain syndromes, chronic plantar fasciitis, lateral epicondylitis(tennis elbow), degenerative coxarthrosis (osteoarthritis of the hip joint), anal fissure and urinary incontinence in subjects with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

It was under development for the treatment of vulvodynia.

Ipsen overview

Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatic diseases. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Quick View Abobotulinumtoxina LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Abobotulinumtoxina
Administration Pathway
  • Intradermal
  • Intramuscular
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Musculoskeletal Disorders
  • Ophthalmology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.